

Minimally invasive reoperative aortic valve replacement: a systematic review and meta-analysis

Kevin Phan^{1,2}, Jessie J. Zhou¹, Nithya Niranjani¹, Marco Di Eusanio^{1,3}, Tristan D. Yan^{1,4}

¹The Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia; ²Westmead Hospital, Sydney Medical School, University of Sydney, Sydney, Australia; ³Cardiovascular Surgery Department, Sant'Orsola-Malpighi Hospital, Bologna University, Bologna, Italy; ⁴Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia

Correspondence to: Tristan D. Yan. Professor of Cardiovascular and Thoracic Surgery, The Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia. Email: tristanyan@annalscts.com.

Background: With prolonged life expectancy and more frequent use of biological prostheses, an increasingly higher proportion of patients are undergoing aortic valve replacement (AVR) after previous sternotomy. We critically appraised the quantity and quality of evidence to demonstrate the efficacy and safety of the minimally invasive (MIrAVR) versus conventional (CrAVR) approaches for reoperative AVR.

Methods: Electronic searches were performed using six databases from their inception to April 2014. Relevant studies utilizing a MIrAVR were identified. Data were extracted and analyzed according to predefined clinical endpoints.

Results: Four single-arm and seven comparative observational studies including a total of 441 MIrAVR patients were included for quality assessment, data extraction and analysis. In-hospital mortality ranged from 0-9.5%, and was similar between the MIrAVR and CrAVR groups (RR, 0.77; 95% CI, 0.39-1.54; P=0.46). Stroke rates ranged from 2.6-8% and were also similar between the two cohorts. The rates of pacemaker implantation, renal failure and reoperation for bleeding were not significantly different between the two groups. There were no reports of myocardial infarctions in the included studies. No significant difference in hospital stay was observed for the MIrAVR versus CrAVR group.

Conclusions: The current literature suggests that MIrAVR has similar efficacy and mortality outcomes compared to CrAVR without compromise to myocardial protection or hospitalization duration. It appears to be a valid alternative option for patients requiring reoperative AVR.

Keywords: Minimally invasive; aortic valve replacement (AVR); reoperative; systematic review



Submitted Jul 13, 2014. Accepted for publication Jul 20, 2013.

doi: 10.3978/j.issn.2225-319X.2014.08.02

View this article at: <http://dx.doi.org/10.3978/j.issn.2225-319X.2014.08.02>

Introduction

Given extended life expectancies and improved survival rates of modern procedures, there is an increasing number of patients undergoing reoperative cardiac surgery (1). Conventional reoperative aortic valve replacement (CrAVR) is particularly challenging, often due to severe calcified aortic stenosis following previous sternotomy for coronary artery bypass grafting (CABG) (2) or degeneration of aortic bioprostheses (3). These complicated cases are often associated with prolonged cross-clamp and cardiopulmonary

bypass durations, increased blood loss and poorer survival rates (4,5).

Minimally invasive rAVR (MIrAVR) is an alternative approach to conventional sternotomy with comparable mortality rates but reduced hospitalization, intensive care stay and improved cosmesis (6). While minimally invasive valvular surgery is becoming increasingly accepted for primary operations, MIrAVR has not been well defined. MIrAVR may be advantageous in avoiding large, open dissections, minimizing trauma and reducing injury to cardiac structures such as previous patent grafts (7,8),

while still having the benefits of reduced intensive care and hospital stay. On the other hand, MlRrAVR procedures are technically more demanding for the operating surgeon and myocardial protection may be a concern (9), especially in patients with patent coronary artery bypass grafts. A systematic review and meta-analysis was carried out to assess the current evidence on the efficacy and safety of MlRrAVR versus CrAVR.

Methods

Literature search strategy

Electronic searches were performed using Ovid Medline, PubMed, Cochrane Central Register of Controlled Trials (CCTR), Cochrane Database of Systematic Reviews (CDSR), ACP Journal Club, and Database of Abstracts of Review of Effectiveness (DARE) from their date of inception to April 2014. To achieve the maximum sensitivity of the search strategy, we combined the terms: “minimally invasive OR ministernotomy OR hemisternotomy OR partial upper sternotomy OR minithoracotomy” AND “aortic valve replacement OR AVR” AND “reoperative OR redo OR resternotomy” as either key words or MeSH terms. The reference lists of all retrieved articles were reviewed for further identification of potentially relevant studies, assessed using the inclusion and exclusion criteria. Expert academic cardiothoracic surgeons (M.D.E, T.D.Y) were consulted as to whether they knew of any unpublished data.

Selection criteria

Eligible studies for the present systematic review and meta-analysis were those in which patient cohorts underwent MlRrAVR after a previous sternotomy and operation. Studies that did not include mortality or complications as endpoints were excluded. When institutions published duplicate studies with accumulating numbers of patients or increased lengths of follow-up, only the most complete reports were included for quantitative assessment at each time interval. All publications were limited to those involving human subjects and in the English language. Abstracts, case reports, conference presentations, editorials, reviews and expert opinions were excluded.

Data extraction and critical appraisal

All data were extracted from article texts, tables and figures.

Two investigators independently reviewed each retrieved article (K.P, J.J.Z). Discrepancies between the two reviewers were resolved by discussion and consensus (K.P, J.J.Z, N.N). If the study provided medians and interquartile ranges instead of means and standard deviations (SDs), we imputed the means and SDs as described by Hozo *et al.* (10). As quality scoring is controversial in meta-analyses of observational studies, two reviewers (K.P, J.J.Z) independently appraised each article using the criteria for case series quality assessment recommended by the National Health Service Center for Reviews and Dissemination (11) (University of York, Heslington, United Kingdom). The final results were reviewed by senior investigators (M.D.E, T.D.Y).

Statistical analysis

The relative risk (RR) was used as a summary statistic. In the present study, both fixed- and random-effect models were tested. In the fixed-effects model, it was assumed that the treatment effect in each study was the same, whereas in the random-effects model, it was assumed that there were variations between studies. χ^2 tests were used to study heterogeneity between trials. The I^2 statistic was used to estimate the percentage of total variation across studies, owing to heterogeneity rather than chance, with values greater than 50% considered as substantial heterogeneity. If there was substantial heterogeneity, the possible clinical and methodological reasons for this were explored qualitatively. In the present meta-analysis, the results using the random-effects model were reported to take into account the possible clinical diversity and methodological variation between studies. Specific analyses considering confounding factors were not possible because raw data were not available. Data are presented as means $\pm$ SD. Weighted means (WM) were calculated by determining the total number of events divided by total sample size. Pearson's statistic was used to calculate correlation for meta-regression meta-analysis. All P values were 2-sided. All statistical analysis was conducted with Review Manager Version 5.2.1 (Cochrane Collaboration, Software Update, Oxford, United Kingdom) and the metafor package for R version 3.01.

Results

Literature search

A total of 685 references were identified through the six




Figure 1 PRISMA search strategy for the present systematic review and meta-analysis.

electronic database searches (*Figure 1*). After exclusion of duplicate or irrelevant references, 566 potentially relevant articles were retrieved. After detailed evaluation of these articles, 27 studies remained for assessment. After applying the selection criteria, 11 articles (7,8,12-20) were selected for qualitative analysis. Of these, 7 observational studies (7,8,14,15,17,19,20) were included for quantitative analysis. The study characteristics are summarized in *Table 1*. Of the 11 included articles, 441 patients underwent rAVR via a MIVrAVR, and 1,145 patients via the conventional sternotomy approach. Baseline patient characteristics and myocardial protection strategies are summarized in *Tables 2* and *3*, respectively.

Quality appraisal

All included studies except one (15) were retrospective, observational studies, seven of which had comparative control groups. There were four studies which included

greater than 50 patients undergoing rAVR by a MIVrAVR (7,14,15,17), while seven studies assessed fewer than 50 patients (8,12,13,16,18-20). A partial upper sternotomy or ministernotomy approach for resternotomy was used in eight studies (7,8,13,14,16-18,20) (n=302, while a minithoracotomy approach was employed by three studies (12,15,19) (n=139). Only five studies reported mean or median follow-up, which were all greater than or equal to 24 months (7,14,16,18,19).

The cardioplegia strategy was reported in all included studies, with three studies using retrograde approach (7,11,18), two studies using antegrade approach (16,19), five studies using the combined approach (6,12,14,15,17), and one study using either approach (13). Temperatures used during cardiopulmonary bypass (CPB) were reported in all included studies except for two (12,17). CPB duration was reported in all but three studies (12,13,15), while cross-clamp duration was not reported in three studies (13,15,17). In-hospital mortality was reported in all included

Table 1 Summary characteristics of included studies in the present systematic review and meta-analysis

First author	Year	Treatment center	Study period	Study design	n (MIRAVR)	n (CrAVR)	Minimally invasive reoperative approach	Mean follow-up (months)
Byrne	1999	Boston	1996-1998	OS, R	20	19	Partial upper ministernotomy	-
Grossi	2000	New York	1996-2000	OS, R	42	0	Right minithoracotomy	-
Svensson	2001	Burlington	-	OS, R	18	0	J ministernotomy	-
Mihaljevic	2004	Boston	1996-2003	OS, R	63	134	Upper ministernotomy	39 ^M (IR 1-84)
Sharony	2006	New York	1995-2002	OS, P	61	160	Minithoracotomy	-
Bakir	2007	Aalst	1999-2005	OS, R	19	0	J ministernotomy	23.6±19.7
Totaro	2009	Milan	1997-2007	OS, R	77	695	Upper ministernotomy (T and L)	-
Gaeta	2010	Messina	1997-2007	OS, R	16	0	J or reversed-T ministernotomy	58 ^M (IR 11-124)
Pineda	2013	Florida	2005-2011	OS, R	36	41	Right minithoracotomy	24
Mikus	2013	Cotignola	2007-2012	OS, R	38	42	Upper J ministernotomy	-
Kaneko	2014	Boston	1997-2011	OS, R	51	54	Upper ministernotomy	36 ^M (IR 14-64)

MIRAVR, minimally invasive reoperative aortic valve replacement; CrAVR, conventional reoperative aortic valve replacement; n, number of patients; OS, observational study; R, retrospective; P, prospective; ^M, median; IR, interquartile range; NR, not reported; Dashed lines indicate value was not reported.

Table 2 Baseline characteristics of patients undergoing reoperative aortic valve replacement via a minimally invasive approach

First author	n	Mean age (years)	Male	LVEF	NYHA class III-IV	AS	AR	DM	PVD	Strokes	CVA	Renal failure	COPD	Previous CABG
Byrne	20	69 ^M (IR 39-93)	80	54 ^M (IR 20-78)	50	-	-	-	-	-	-	-	-	55
Grossi	42	-	-	-	-	-	-	-	-	-	-	-	-	-
Svensson	18	-	-	-	-	-	-	-	-	-	-	-	-	-
Mihaljevic	63	75 ^M (IR 31-93)	75	-*	37	-	63	-	-	-	-	-	-	63
Sharony	61	63.4±1.3	64	-	-	-	-	14.3	-	-	-	-	13	-
Bakir	19	73.6±11.4	-	58.1±15	47.3	-	-	15.8	-	-	-	15.8	15.8	63.2
Totaro	77	62±13	61	53±12	-	-	-	-	-	-	-	-	-	-
Gaeta	16	-	-	-	-	-	-	-	-	6.3	-	-	-	100
Pineda	36	75.3±9	92	55 ^M (IR 41-60)	-	-	-	64	17	-	14	-	-	86
Mikus	38	76±11	55.3	55 ^M	-	73.6	-	21.1	31.6	-	2.6	-	21.1	46
Kaneko	51	83.3±2.7	70.6	55 ^M (IR 50-60)	62.7	78.4	5.9	31.4	-	9.8	9.8	2	-	92.2
Minimum	-	62	55.3	53	37	73.6	5.9	14.3	17	6.3	2.6	2	13	46
Maximum	-	83.3	92	55	62.7	78.4	63	64	31.6	9.8	14	15.8	21.1	100
Weighted Mean	-	71.2	69.2	49.9	48.7	NA	NA	30.0	NA	NA	8.8	NA	NA	71.7

Data presented are expressed in % unless otherwise stated; n, number of patients; PVD, peripheral vascular disease; AS, aortic stenosis; AR, aortic regurgitation; ^M, median; IR, interquartile range; DM, diabetes mellitus; *, 19 out of 63 patients had LVEF ≤40%; Dashed lines indicate value was not reported; NA, not appropriate due to low reporting of outcome; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; CVA, cerebrovascular accident; COPD, chronic obstructive pulmonary disease; CABG, coronary artery bypass graft.

Table 3 Myocardial protection strategies for included studies

Study	Cardioplegia strategy	CPB temperature (°C)	Patent CABG grafts occluded
Byrne	Retrograde, after initial antegrade dose	20-25	No
Grossi	Retrograde	NR	NR
Svensson	Antegrade + retrograde	22	No
Mihaljevic	Antegrade or retrograde	20-22	No
Sharony	Antegrade + retrograde	25-28	NR
Bakir	Antegrade + retrograde	26.2±4	NR
Totaro	Antegrade	NR	No
Gaeta	Antegrade +/- retrograde	24-33	Yes
Pineda	Retrograde, after initial antegrade dose	28	No
Mikus	Antegrade	Normothermia	No
Kaneko	Antegrade + retrograde	28-32 (without patent LITA) 20-30 (with patent LITA)	No

CPB, cardiopulmonary bypass; NR, not reported; +, indicates combined strategy; LITA, left internal thoracic artery; CABG, coronary artery bypass graft.

studies. Stroke outcomes were reported in seven studies (7,13,14,16,18-20), reoperations for bleeding in six studies (7,14,16,18-20) and myocardial infarctions in four studies (13,14,18,20). The percentage of patients with previous coronary bypass grafting (CABG) operations was reported in seven studies (7,8,14,16,18-20).

Assessment of mortality and morbidity

In-hospital mortality outcomes are outlined in *Table 4*, with a WM of 4.1% (range: 0-9.5%) for the 11 included studies. Seven comparative observational studies investigating rAVR via MlRrAVR versus CrAVR were available for meta-analysis. The risk of in-hospital mortality was not significantly

different between MlRrAVR and CrAVR groups (3.8% *vs.* 5.4%; RR, 0.77; 95% CI, 0.39-1.54; $P=0.46$; $I^2=17\%$; *Figure 2*). There was also a significant negative correlation between midpoint of study period and in-hospital mortality ($r^2=0.6884$; $P=0.021$; *Figure 3*).

The rates of stroke ranged from 2.6-8%, with a WM of 5.7%. Meta-analysis also showed similar rates of stroke between MlRrAVR and CrAVR cohorts (5.9% *vs.* 3.2%; RR, 1.88; 95% CI, 0.75-4.68; $P=0.18$; $I^2=0\%$; *Figure 4*). No myocardial infarctions were reported by the included studies. The WM incidence of renal failure was 2.3% (range: 0-5.3%), and this was not significantly different between MlRrAVR versus CrAVR (1.3% *vs.* 5.7%; RR, 0.33, 95% CI, 0.10-1.04; $P=0.06$; $I^2=0\%$). Reoperation for bleeding ranged from 0-21%, but was not significantly different between MlRrAVR and CrAVR cohorts (3.0% *vs.* 4.4%; RR, 0.72; 95% CI, 0.25-2.06; $P=0.55$; $I^2=21\%$). Blood transfusion requirements were reported in three studies, with a WM of 56.2% (range: 0-72%). Pacemaker implantation requirements ranged from 0-10.5%, while wound infection occurred in a WM of 1.5% of cases (range: 0-5.3%). Hospital stay duration was reported by eight studies, and ranged from 6.9-12.9 days (WM: 8.5 days). Intensive care unit (ICU) stay duration was reported by seven studies, and ranged from 1.1-3 days (WM: 2.1 days). No difference in ICU stay was observed between MlRrAVR versus CrAVR cohorts. Hospital stay was also similar for the MlRrAVR versus CrAVR group (WMD, -0.62 days; 95% CI, -2.20-0.96; $P=0.44$; $I^2=91\%$; *Figure 5*).

Assessment of operative outcomes

Cross-clamp duration ranged from 51-93 minutes, with a WM of 78.4 minutes. CPB duration ranged from 67-156 minutes, with a WM of 133.6 minutes. No significant difference between MlRrAVR and CrAVR was observed for cross-clamp duration ($P=0.67$; *Figure 6*) or CPB duration ($P=0.40$; *Figure 7*). The rate of conversion was low, with a WM of 0.9%, ranging from 0-2.8%. The proportion of patients using aortic, femoral arterial, femoral venous and right atrial cannulation is reported in *Table 5*.

Discussion

Reoperative aortic valve surgery represents a surgical challenge associated with increased mortality rates and complications (21). This is particularly pertinent for patients with previous sternotomy for CABG operations, where

Table 4 Assessment of morbidity and mortality in reoperative aortic valve replacement via a minimally invasive approach

First author	n	In-hospital mortality	Strokes	MI	Renal failure	Prolonged ventilation	Reop for bleeding	Blood transfusion	RBC units transferred	Pace-maker	Endocarditis	Wound infection	Sepsis	Hospital stay (days)	ICU stay (days)
Byrne	20	0	-	-	0	-	-	-	3.1±3	10	0	0	-	6.9±2.9	-
Grossi	42	9.5	-	-	-	-	-	-	-	-	-	-	-	8 ^{M*}	1.1
Svensson	18	0	5.6	0	-	-	-	-	-	-	-	-	-	-	-
Mihaljevic	63	5	6	0	-	-	0	-	-	-	-	2	-	7 ^M (IR 3-44)	-
Sharony	61	6.6	-	-	-	-	-	-	-	-	-	-	-	-	-
Bakir	19	5.3	5.3*	-	5.2	-	21	-	2.4±3.7	-	-	5.3	-	12.9±5.7	2.9±2.6
Totaro	77	3.8	-	-	-	9	-	-	-	-	-	-	-	10±7	2.1±3.7
Gaeta	16	0	6.3^	0	0	6.3	0	0	0.9±1.2	0	0	0	0	7.5±2.6	1.6±1.1
Pineda	36	0	8	-	3	11	0	72	1 ^M (IR 0-2)	-	-	0	-	7 ^M (IR 5-10)	2 ^M (IR 1.71-4.04)
Mikus	38	2.6	2.6	0	5.3	-	7.9	-	2 ^M	10.5	2.6	-	0	-	2 ^M
Kaneko	51	3.9	5.9	-	0	-	7.8	62.7	3 ^M (IR 2-4)	-	0	-	2	9 ^M (IR 7-15)	3 ^M (IR 1.38-5.38)
Minimum	-	0	2.6	0	0	6.3	0	0	0.9	0	0	0	0	6.9	1.1
Maximum	-	9.5	8	0	5.3	11	21	72	3.1	10.5	2.6	5.3	2	12.9	3
Weighted mean	-	4.1	5.7	0	2.3	9.2	4.9	56.2	2.2	8.1	0.8	1.5	1.0	8.5	2.1

Data presented are expressed in % unless otherwise stated; n, number of patients; *, due to CVA; ^, due to TIA; ^M, median; RBC, red blood cells; MI, myocardial infarction; ICU, intensive care unit; dashed lines indicate value was not reported; IR, interquartile range.




Figure 2 Forest plot of the relative risk of in-hospital mortality after minimally invasive reoperative aortic valve replacement (MIrAVR) versus conventional reoperative aortic valve replacement (CrAVR).




Figure 3 Bubble chart showing correlation between the midpoint of the study period and in-hospital mortality rate. Studies with $n \leq 20$ and with mixed concomitant valve and arch surgery were excluded. The solid line indicates the correlation trend line, while dotted lines indicate the 95% confidence interval.




Figure 4 Forest plot of the relative risk of perioperative stroke after minimally invasive reoperative aortic valve replacement (MIrAVR) versus conventional reoperative aortic valve replacement (CrAVR).




Figure 5 Forest plot for the mean difference in length of hospital stay after minimally invasive reoperative aortic valve replacement (MIRAVR) versus conventional reoperative aortic valve replacement (CrAVR).




Figure 6 Forest plot for the mean difference in cross-clamp duration with minimally invasive reoperative aortic valve replacement (MIRAVR) versus conventional reoperative aortic valve replacement (CrAVR).




Figure 7 Forest plot for the mean difference in cardiopulmonary bypass duration with minimally invasive reoperative aortic valve replacement (MIRAVR) versus conventional reoperative aortic valve replacement (CrAVR).

injury to patent grafts represents a serious concern (8). In this setting, the MIRAVR may avoid hazardous tissue dissections and reduce surgical trauma but is more technically demanding and potentially associated with sub-optimal myocardial protection strategies (7,9). The safety and efficacy of MIRAVR were investigated in the present meta-analysis and systematic review.

While comparable mortality rates and complications have been reported for MIRAVR and CrAVR, the outcomes for rAVR are not well established. From the results of the present meta-analysis, in-hospital mortality was not found to be significantly different between MIRAVR and

CrAVR groups. Mortality rates ranged from 0-9.5% for the MIRAVR. The in-hospital mortality rates also negatively correlated with the midpoint of the study period, suggesting improvement in survival outcomes over time (*Figure 3*), a trend that may continue in the future. This may be partially explained by the learning curve associated with minimally invasive techniques, with lower mortality rates reported in recent years (0-3.9%). The incidences of stroke were also comparable between the MIRAVR and CrAVR cohorts (5.9% *vs.* 3.2%; $P=0.18$ and were similar to values reported by previous meta-analyses on primary AVR cases. While it is expected that the reduced invasiveness of MIRAVR

Table 5 Operative outcomes of patients undergoing reoperative aortic valve replacement via a minimally invasive approach

First author	n	Cross-clamp (min)	CPB (min)	Rate of conversion	Aortic cannulation	Femoral artery cannulation	Femoral vein cannulation	Direct right atrium cannulation	Other
Byrne	20	93±48	147±52	–	10	40	40	10	50
Grossi	42	86±36	–	0	–	–	–	–	–
Svensson	18	–	–	–	–	–	–	–	–
Mihaljevic	63	82 ^M (IR 38-229)	141 ^M (IR 59-300)	–	–	–	–	100	–
Sharony	61	–	–	–	–	–	–	–	–
Bakir	19	87.4±32.7	133.1±54.4	0	53	47	94.7	5.3	–
Totaro	77	–	156±52	1.2	88	12	–	–	–
Gaeta	16	72±20	119.7±38.1	–	75	25	–	–	–
Pineda	36	90 ^M (IR 76-99)	134 ^M (IR 119-146)	2.8	–	–	–	–	–
Mikus	38	51 ^M	67 ^M	0	100	–	–	100	–
Kaneko	51	73 ^M (IR 62-92)	139 ^M (IR 125-180)	–	11.8	21.6	94.1	5.9	66.6
Minimum	–	51	67	0	10	12	40	5.9	–
Maximum	–	93	156	2.8	100	47	94.7	100	–
Weighted mean	–	78.4	133.6	0.9	61.5	22.5	82.1	61.6	–

n, number of patients; CPB, cardiopulmonary bypass duration; ^M, median; IR, interquartile range; dashed lines indicate value was not reported.

would reduce reoperations required for bleeding and transfusions, there were no significant differences found between the cohorts, a result possibly attributable to the low statistical power and small sample size of the included studies. No significant reduction in hospital stay was noted in the MlRrAVR group. Overall, MlRrAVR appears to have comparable complication rates and length of stay compared with CrAVR, lending support to its role as a safe alternative to median sternotomy for reoperative AVR.

The procedural duration of AVR is of great clinical interest, as prolonged cross-clamp and CPB durations have been shown to be associated with inflammation and poorer surgical outcomes (22,23). In the present study, the cross-clamp and CPB durations were similar between minimally invasive and conventional sternotomy cohorts for rAVR. Considering limitations in both surgical vision and maneuverability in a limited working space, this outcome is unexpected. However, by minimizing the surgical isolation of the heart often completed on CPB during CrAVR, MlRrAVR may reduce the overall CPB time. In addition, disparities in operational duration may also be mitigated with the evolution of technical skill and experience in minimally invasive surgery, traversing the initial learning curve phase. The introduction of sutureless

AVR technologies will further obviate and alleviate the technical challenges involved in traditional AVR (24,25). Given that annular sutures do not need to be securely tied down to hold the valve in place, the sutureless approach facilitates smaller incisions and shorter cross-clamp, CPB and procedural durations, ideal for reoperations (26). However, it remains to be seen if these newer sutureless valve technologies are suitable for reoperative aortic valve operations.

The major concern in minimally invasive reoperations is the optimal myocardial protection strategy (8,9,20). Typically, the standard approach involves isolation and occlusion of patent CABG grafts, antegrade or retrograde cardioplegia infusion, and moderate or mild hypothermia. These conditions are easily met during conventional reoperative aortic valve surgery. However, during minimally invasive reoperative surgery, given the reduced surgical field of ministernotomy and minithoracotomy incisions, it is difficult to isolate and control internal thoracic artery (ITA) grafts during clamping (9). In these cases, an alternative approach is to leave patent grafts unoccluded, resulting in constant perfusion of the myocardium with oxygenated blood. Cardioplegia is well delivered and deeper levels of systemic hypothermia are used to compensate for the sub-

optimal conductance of myocardial protection. As a result, perfect arrest is not always achieved, and with the heart still fibrillating, the risk of postoperative myocardial infarction becomes a serious concern. Notably, the present study showed the incidence of myocardial infarction to be nil in all studies. As such, the current evidence seems to suggest that, in carefully selected patients, such ‘no-touch’ (9) hypothermic cardioplegia provides acceptable myocardial protection. Furthermore, proponents of MlR-AVR have also suggested that by avoiding dissection and occlusion of grafts, there is reduced risk of ITA injury and embolism due to manipulation of atherosclerotic vein grafts (8,13,19,27).

Limitations

The current meta-analysis is limited by small, retrospective studies with inadequate statistical power, which may have underestimated complication rates. Resource-related outcomes such as economic costs, pain scores and quality of life outcomes were not reported by the included studies. The heterogeneity of cross-clamp and CPB outcomes, as well as hospitalization time, may be accounted for by considering the inherent variation in the patient populations, which comprise patients with a wide variety of previous cardiac operations. This ranged from prior CABG and patent grafts to prior sternotomy for AVR or mitral valve surgery with concurrent surgical ablation, with the latter known to have different postoperative outcomes (28,29).

Given the technical challenges involved in minimally invasive reoperative surgery, it is likely that the current evidence is based on outcomes from highly experienced expert surgeons at high-volume academic centers. As such, the current results may only be representative of carefully selected patient and surgeon populations, and may not be reproducible for surgeons with lesser experience. Variation in procedural outcome may also be due to inherent differences between the ministernotomy and minithoracotomy approaches employed. Furthermore, long-term outcomes were not available, making it difficult to comprehensively evaluate the comparative risks and benefits of MlR-AVR and Cr-AVR. Given the promising data to date, future registry or prospectively randomized trials should be carried out to more definitively assess the MlR-AVR.

Conclusions

Minimally invasive approaches to r-AVR represent a potential alternative to median sternotomy, with similar mor-

talidity and morbidity outcomes, and adequate myocardial protection. MlR-AVR appears to have acceptable outcomes in carefully selected patients, and these are likely to further improve with the learning curve of the procedure and emergence of sutureless valve technology. However, there remains a lack of robust clinical evidence and adequately powered, randomized studies are warranted to comprehensively evaluate the efficacy and safety of MlR-AVR.

Acknowledgements

Disclosure: The authors declare no conflict of interest.

References

1. Brown JM, O'Brien SM, Wu C, et al. Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database. *J Thorac Cardiovasc Surg* 2009;137:82-90.
2. Hirose H, Gill IS, Lytle BW. Redo-aortic valve replacement after previous bilateral internal thoracic artery bypass grafting. *Ann Thorac Surg* 2004;78:782-5.
3. Vogt PR, Brunner-LaRocca H, Sidler P, et al. Reoperative surgery for degenerated aortic bioprostheses: predictors for emergency surgery and reoperative mortality. *Eur J Cardiothorac Surg* 2000;17:134-9.
4. Maganti M, Rao V, Armstrong S, et al. Redo valvular surgery in elderly patients. *Ann Thorac Surg* 2009;87:521-5.
5. Langanay T, Verhoye JP, Ocampo G, et al. Current hospital mortality of aortic valve replacement in octogenarians. *J Heart Valve Dis* 2006;15:630-7; discussion 637.
6. Phan K, Xie A, Di Eusanio M, et al. A Meta-Analysis of Minimally Invasive Versus Conventional Sternotomy for Aortic Valve Replacement. *Ann Thorac Surg* 2014;98:1499-511.
7. Kaneko T, Loberman D, Gosev I, et al. Reoperative aortic valve replacement in the octogenarians-minimally invasive technique in the era of transcatheter valve replacement. *J Thorac Cardiovasc Surg* 2014;147:155-62.
8. Byrne JG, Aranki SF, Couper GS, et al. Reoperative aortic valve replacement: partial upper hemisternotomy versus conventional full sternotomy. *J Thorac Cardiovasc Surg* 1999;118:991-7.
9. Kaneko T, Nauta F, Borstlap W, et al. The “no-dissection” technique is safe for reoperative aortic valve replacement with a patent left internal thoracic artery graft. *J Thorac Cardiovasc Surg* 2012;144:1036-40.

10. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol* 2005;5:13.
11. Chien WT, Norman I. The effectiveness and active ingredients of mutual support groups for family caregivers of people with psychotic disorders: a literature review. *Int J Nurs Stud* 2009;46:1604-23.
12. Grossi EA, LaPietra A, Bizakis C, et al. Minimal access reoperative mitral and aortic valve surgery. *Curr Cardiol Rep* 2000;2:572-4.
13. Svensson LG, Nadolny EM, Kimmel WA. Minimal access aortic surgery including re-operations. *Eur J Cardiothorac Surg* 2001;19:30-3.
14. Mihaljevic T, Cohn LH, Unic D, et al. One thousand minimally invasive valve operations: early and late results. *Ann Surg* 2004;240:529-34; discussion 534.
15. Sharony R, Grossi EA, Saunders PC, et al. Minimally invasive reoperative isolated valve surgery: early and mid-term results. *J Card Surg* 2006;21:240-4.
16. Bakir I, Casselman FP, De Geest R, et al. Should minimally invasive aortic valve replacement be restricted to primary interventions? *Thorac Cardiovasc Surg* 2007;55:304-9.
17. Totaro P, Carlini S, Pozzi M, et al. Minimally invasive approach for complex cardiac surgery procedures. *Ann Thorac Surg* 2009;88:462-6; discussion 467.
18. Gaeta R, Lentini S, Raffa G, et al. Aortic valve replacement by ministernotomy in redo patients with previous left internal mammary artery patent grafts. *Ann Thorac Cardiovasc Surg* 2010;16:181-6.
19. Pineda AM, Santana O, Reyna J, et al. Outcomes of reoperative aortic valve replacement via right mini-thoracotomy versus median sternotomy. *J Heart Valve Dis* 2013;22:50-5.
20. Mikus E, Calvi S, Tripodi A, et al. Upper 'J' ministernotomy versus full sternotomy: an easier approach for aortic valve reoperation. *J Heart Valve Dis* 2013;22:295-300.
21. Potter DD, Sundt TM 3rd, Zehr KJ, et al. Operative risk of reoperative aortic valve replacement. *J Thorac Cardiovasc Surg* 2005;129:94-103.
22. Warren OJ, Smith AJ, Alexiou C, et al. The inflammatory response to cardiopulmonary bypass: part 1--mechanisms of pathogenesis. *J Cardiothorac Vasc Anesth* 2009;23:223-31.
23. Rossaint J, Berger C, Van Aken H, et al. Cardiopulmonary bypass during cardiac surgery modulates systemic inflammation by affecting different steps of the leukocyte recruitment cascade. *PLoS One* 2012;7:e45738.
24. Breitenbach I, Wimmer-Greinecker G, Bockeria LA, et al. Sutureless aortic valve replacement with the Trilogy Aortic Valve System: multicenter experience. *J Thorac Cardiovasc Surg* 2010;140:878-84,884.e1.
25. Santarpino G, Pfeiffer S, Concistrè G, et al. REDO aortic valve replacement: the sutureless approach. *J Heart Valve Dis* 2013;22:615-20.
26. Phan K, Tsai YC, Nithya N, et al. Sutureless aortic valve replacement: a systematic review and meta-analysis. *Ann Cardiothorac Surg* 2014. [Epub ahead of print].
27. Dell'Amore A, Del Giglio M, Calvi S, et al. Mini re-sternotomy for aortic valve replacement in patients with patent coronary bypass grafts. *Interact Cardiovasc Thorac Surg* 2009;9:94-7.
28. Phan K, Xie A, La Meir M, et al. Surgical ablation for treatment of atrial fibrillation in cardiac surgery: a cumulative meta-analysis of randomised controlled trials. *Heart* 2014;100:722-30.
29. Phan K, Xie A, Tian DH, et al. Systematic review and meta-analysis of surgical ablation for atrial fibrillation during mitral valve surgery. *Ann Cardiothorac Surg* 2014;3:3-14.

Cite this article as: Phan K, Zhou JJ, Niranjana N, Di Eusania M, Yan TD. Minimally invasive reoperative aortic valve replacement: a systematic review and meta-analysis. *Ann Cardiothorac Surg* 2015;4(1):15-25. doi: 10.3978/j.issn.2225-319X.2014.08.02